Patents Assigned to Biovec, LLC
  • In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
    Patent number: 9388427
    Abstract: A method for treating a renal disease in a subject is disclosed. The method includes administering into a kidney of the subject with an effective amount of a gutless adenoviral vector containing a polynucleotide encoding a therapeutic agent. The gutless adenoviral vector contains the nucleotide sequence of SEQ ID NO:13 or SEQ ID NO:15 and expresses the therapeutic agent in a kidney tissue of the subject.
    Type: Grant
    Filed: January 26, 2009
    Date of Patent: July 12, 2016
    Assignee: BIOVEC, LLC
    Inventors: Lakshman R. Sehgal, Jonathan Wong
  • Vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
    Patent number: 9353383
    Abstract: A method for treating a renal disease in a subject is disclosed. The method includes administering into a kidney of the subject with an effective amount of a gutless adenoviral vector containing a polynucleotide encoding a therapeutic agent. The gutless adenoviral vector contains the nucleotide sequence of SEQ ID NO:13 or SEQ ID NO:15 and expresses the therapeutic agent in a kidney tissue of the subject.
    Type: Grant
    Filed: July 11, 2011
    Date of Patent: May 31, 2016
    Assignee: BIOVEC, LLC
    Inventors: Lakshman R. Sehgal, Jonathan Wong
  • Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
    Patent number: 8420075
    Abstract: The present invention relates to methods and compositions for treatment of cardiovascular and peripheral vascular diseases using ex vivo and in vivo gene delivery technologies. One aspect of the present invention relates to a method for treating a vascular disease by introducing a DNA sequence encoding a TM protein or its variant into a segment of a blood vessel in vivo using a gutless adenovirus vector. Another aspect of the present invention is to provide a method to deliver a gutless adenovirus vector carrying a DNA sequence encoding a TM protein or its variant using a stent.
    Type: Grant
    Filed: March 30, 2010
    Date of Patent: April 16, 2013
    Assignee: Biovec, LLC
    Inventors: Lakshman R. Sehgal, Jonathan Wong
  • In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
    Patent number: 8367056
    Abstract: A method for treating a renal disease in a subject is disclosed. The method includes administering into a kidney of the subject with an effective amount of a gutless adenoviral vector containing a polynucleotide encoding a therapeutic agent. The gutless adenoviral vector contains the nucleotide sequence of SEQ ID NO:13 or SEQ ID NO:15 and expresses the therapeutic agent in a kidney tissue of the subject.
    Type: Grant
    Filed: February 8, 2011
    Date of Patent: February 5, 2013
    Assignee: Biovec, LLC
    Inventors: Lakshman R. Sehgal, Jonathan Wong
  • In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
    Patent number: 8242095
    Abstract: A method for treating a renal disease in a subject is disclosed. The method includes administering into a kidney of the subject with an effective amount of a gutless adenoviral vector containing a polynucleotide encoding a therapeutic agent. The gutless adenoviral vector contains the nucleotide sequence of SEQ ID NO:13 or SEQ ID NO:15 and expresses the therapeutic agent in a kidney tissue of the subject.
    Type: Grant
    Filed: May 12, 2010
    Date of Patent: August 14, 2012
    Assignee: BIOVEC, LLC
    Inventors: Lakshman R. Sehgal, Jonathan Wong
  • In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
    Patent number: 8236300
    Abstract: A method for treating a renal disease in a subject is disclosed. The method includes administering into a kidney of the subject with an effective amount of a gutless adenoviral vector containing a polynucleotide encoding a therapeutic agent. The gutless adenoviral vector contains the nucleotide sequence of SEQ ID NO:13 or SEQ ID NO:15 and expresses the therapeutic agent in a kidney tissue of the subject.
    Type: Grant
    Filed: February 8, 2011
    Date of Patent: August 7, 2012
    Assignee: Biovec, LLC
    Inventors: Lakshman R. Sehgal, Jonathan Wong
  • IN VIVO AND EX VIVO GENE TRANSFER INTO RENAL TISSUE USING GUTLESS ADENOVIRUS VECTORS
    Publication number: 20110307076
    Abstract: A method for treating a renal disease in a subject is disclosed. The method includes administering into a kidney of the subject with an effective amount of a gutless adenoviral vector containing a polynucleotide encoding a therapeutic agent. The gutless adenoviral vector contains the nucleotide sequence of SEQ ID NO:13 or SEQ ID NO:15 and expresses the therapeutic agent in a kidney tissue of the subject.
    Type: Application
    Filed: July 11, 2011
    Publication date: December 15, 2011
    Applicant: BIOVEC, LLC
    Inventors: Lakshman R. SEHGAL, Jonathan Wong
  • In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
    Patent number: 8048410
    Abstract: A method for treating a renal disease in a subject is disclosed. The method includes administering into a kidney of the subject with an effective amount of a gutless adenoviral vector containing a polynucleotide encoding a therapeutic agent. The gutless adenoviral vector contains the nucleotide sequence of SEQ ID NO:13 or SEQ ID NO:15 and expresses the therapeutic agent in a kidney tissue of the subject.
    Type: Grant
    Filed: May 12, 2010
    Date of Patent: November 1, 2011
    Assignee: Biovec, LLC
    Inventors: Lakshman R. Sehgal, Jonathan Wong
  • IN VIVO AND EX VIVO GENE TRANSFER INTO RENAL TISSUE USING GUTLESS ADENOVIRUS VECTORS
    Publication number: 20110196023
    Abstract: A method for treating a renal disease in a subject is disclosed. The method includes administering into a kidney of the subject with an effective amount of a gutless adenoviral vector containing a polynucleotide encoding a therapeutic agent. The gutless adenoviral vector contains the nucleotide sequence of SEQ ID NO:13 or SEQ ID NO:15 and expresses the therapeutic agent in a kidney tissue of the subject.
    Type: Application
    Filed: February 8, 2011
    Publication date: August 11, 2011
    Applicant: BIOVEC, LLC
    Inventors: LAKSHMAN S. SEHGAL, JONATHAN WONG
  • IN VIVO AND EX VIVO GENE TRANSFER INTO RENAL TISSUE USING GUTLESS ADENOVIRUS VECTORS
    Publication number: 20110196022
    Abstract: A method for treating a renal disease in a subject is disclosed. The method includes administering into a kidney of the subject with an effective amount of a gutless adenoviral vector containing a polynucleotide encoding a therapeutic agent. The gutless adenoviral vector contains the nucleotide sequence of SEQ ID NO:13 or SEQ ID NO:15 and expresses the therapeutic agent in a kidney tissue of the subject.
    Type: Application
    Filed: February 8, 2011
    Publication date: August 11, 2011
    Applicant: BIOVEC, LLC
    Inventors: LAKSHMAN R. SEHGAL, JONATHAN WONG
  • IN VIVO AND EX VIVO GENE TRANSFER INTO RENAL TISSUE USING GUTLESS ADENOVIRUS VECTORS
    Publication number: 20100247487
    Abstract: A method for treating a renal disease in a subject is disclosed. The method includes administering into a kidney of the subject with an effective amount of a gutless adenoviral vector containing a polynucleotide encoding a therapeutic agent. The gutless adenoviral vector contains the nucleotide sequence of SEQ ID NO:13 or SEQ ID NO:15 and expresses the therapeutic agent in a kidney tissue of the subject.
    Type: Application
    Filed: May 12, 2010
    Publication date: September 30, 2010
    Applicant: BIOVEC, LLC
    Inventors: Lakshman R. SEHGAL, Jonathan Wong
  • IN VIVO AND EX VIVO GENE TRANSFER INTO RENAL TISSUE USING GUTLESS ADENOVIRUS VECTORS
    Publication number: 20100249221
    Abstract: A method for treating a renal disease in a subject is disclosed. The method includes administering into a kidney of the subject with an effective amount of a gutless adenoviral vector containing a polynucleotide encoding a therapeutic agent. The gutless adenoviral vector contains the nucleotide sequence of SEQ ID NO:13 or SEQ ID NO:15 and expresses the therapeutic agent in a kidney tissue of the subject.
    Type: Application
    Filed: May 12, 2010
    Publication date: September 30, 2010
    Applicant: BIOVEC, LLC
    Inventors: Lakshman R. SEHGAL, Jonathan Wong
  • Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
    Patent number: 7803365
    Abstract: The present invention relates to methods and compositions for treatment of cardiovascular and peripheral vascular diseases using ex vivo and in vivo gene delivery technologies. One aspect of the present invention relates to a method for treating a vascular disease by introducing a DNA sequence encoding a TM protein or its variant into a segment of a blood vessel in vivo using a gutless adenovirus vector. Another aspect of the present invention is to provide a method to deliver a gutless adenovirus vector carrying a DNA sequence encoding a TM protein or its variant using a stent.
    Type: Grant
    Filed: March 13, 2007
    Date of Patent: September 28, 2010
    Assignee: Biovec, LLC
    Inventors: Lakshman R. Sehgal, Jonathan Wong
  • EX VIVO AND IN VIVO EXPRESSION OF THE THROMBOMODULIN GENE FOR THE TREATMENT OF CARDIOVASCULAR AND PERIPHERAL VASCULAR DISEASES
    Publication number: 20100240740
    Abstract: The present invention relates to methods and compositions for treatment of cardiovascular and peripheral vascular diseases using ex vivo and in vivo gene delivery technologies. One aspect of the present invention relates to a method for treating a vascular disease by introducing a DNA sequence encoding a TM protein or its variant into a segment of a blood vessel in vivo using a gutless adenovirus vector. Another aspect of the present invention is to provide a method to deliver a gutless adenovirus vector carrying a DNA sequence encoding a TM protein or its variant using a stent.
    Type: Application
    Filed: March 30, 2010
    Publication date: September 23, 2010
    Applicant: BioVec, LLC
    Inventors: Lakshman R. SEHGAL, Jonathan WONG
  • Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
    Patent number: 7713522
    Abstract: The present invention relates to methods and compositions for treatment of cardiovascular and peripheral vascular diseases using ex vivo and in vivo gene delivery technologies. One aspect of the present invention relates to a method for treating a vascular disease by introducing a DNA sequence encoding a TM protein or its variant into a segment of a blood vessel ex vivo using a gutless adenovirus vector. Another aspect of the present invention is to provide a gutless adenovirus vector carrying a transgene, such as a gene encoding TM protein or its variant.
    Type: Grant
    Filed: July 28, 2008
    Date of Patent: May 11, 2010
    Assignee: BioVec, LLC
    Inventors: Lakshman R. Sehgal, Jonathan Wong
  • Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
    Patent number: 7687058
    Abstract: The present invention relates to methods and compositions for treatment of cardiovascular and peripheral vascular diseases using ex vivo and in vivo gene delivery technologies. One aspect of the present invention relates to a method for treating a vascular disease by introducing a DNA sequence encoding a TM protein or its variant into a segment of a blood vessel ex vivo using a gutless adenovirus vector. Another aspect of the present invention is to provide a gutless adenovirus vector carrying a transgene, such as a gene encoding TM protein or its variant.
    Type: Grant
    Filed: July 28, 2008
    Date of Patent: March 30, 2010
    Assignee: BioVec, LLC
    Inventors: Lakshman R. Sehgal, Jonathan Wong
  • Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
    Patent number: 7670597
    Abstract: The present invention relates to methods and compositions for treatment of cardiovascular and peripheral vascular diseases using ex vivo and in vivo gene delivery technologies. One aspect of the present invention relates to a method for treating a vascular disease by introducing a DNA sequence encoding a TM protein or its variant into a segment of a blood vessel ex vitro using a gutless adenovirus vector. Another aspect of the present invention is to provide a method to deliver a gutless adenovirus vector carrying a DNA sequence encoding a TM protein or its variant using a stent.
    Type: Grant
    Filed: August 15, 2006
    Date of Patent: March 2, 2010
    Assignee: Biovec, LLC
    Inventors: Lakshman R. Sehgal, Jonathan Wong
  • Composition for Preserving Platelets and Method of Using the Same
    Publication number: 20090263781
    Abstract: The present invention relates to compositions and methods for storing platelets to preserve the function and freshness of the platelets. More particularly, the present invention relates to the use of a preservative composition having an antiplatelet agent, an anticoagulant, and an oxygen carrier, for maintaining the freshness of platelets. Additionally, the composition may also contain an ultra-short acting broad spectrum anti-microbial agents. The preservative composition may be used to store platelets in a liquid state, a frozen state, or a freeze-dried state.
    Type: Application
    Filed: May 8, 2009
    Publication date: October 22, 2009
    Applicant: BIOVEC, LLC.
    Inventors: Lakshman R. Sehgal, Shaker Mousa
  • COMPOSITION FOR PRESERVING PLATELETS AND METHOD OF USING THE SAME
    Publication number: 20090253115
    Abstract: The present invention relates to compositions and methods for storing platelets to preserve the function and freshness of the platelets. More particularly, the present invention relates to the use of a preservative composition having an antiplatelet agent, an anticoagulant, and an oxygen carrier, for maintaining the freshness of platelets. Additionally, the composition may also contain an ultra-short acting broad spectrum anti-microbial agents. The preservative composition may be used to store platelets in a liquid state, a frozen state, or a freeze-dried state.
    Type: Application
    Filed: May 11, 2009
    Publication date: October 8, 2009
    Applicant: BIOVEC, LLC.
    Inventors: Lakshman R. SEHGAL, Shaker Mousa
  • In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
    Publication number: 20090238795
    Abstract: A method for treating a renal disease in a subject is disclosed. The method includes administering into a kidney of the subject with an effective amount of a gutless adenoviral vector containing a polynucleotide encoding a therapeutic agent. The gutless adenoviral vector contains the nucleotide sequence of SEQ ID NO:13 or SEQ ID NO:15 and expresses the therapeutic agent in a kidney tissue of the subject.
    Type: Application
    Filed: January 26, 2009
    Publication date: September 24, 2009
    Applicant: BIOVEC, LLC.
    Inventors: Lakshman R. Sehgal, Jonathan Wong